Kinetic interaction between theophylline and a newly developed quinolone, NY-198.
The effect of a newly developed quinolone, NY-198, on the pharmacokinetics and metabolism of theophylline was investigated under steady-state conditions in six male healthy volunteers, in a crossover fashion. A sustained-release theophylline formulation (200 mg twice daily at 12 h intervals) was received as monotherapy or coadministration with NY-198 (200 mg twice daily at 12 h intervals). No significant change in the pharmacokinetic parameters of theophylline was observed during coadministration of NY-198. No significant change in urinary excretion of theophylline and its metabolites was also observed. These findings indicate that NY-198 does not influence the pharmacokinetics of theophylline and we can suggest that quinoline derivatives have less effect on theophylline disposition than 1,8-naphthyridine derivatives among quinolones.
Kuzuya
T
T
Department of Hospital Pharmacy, Nagoya University, School of Medicine, Japan.
Takagi
K
K
Apichartpichean
R
R
Muraoka
I
I
Nadai
M
M
Hasegawa
T
T
D042462:4-Quinolones; D000328:Adult; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000493:pharmacokinetics*; D004347:Drug Interactions; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D015363:Quinolones; D013806:Theophylline / Q000097:blood / Q000493:pharmacokinetics*
D042462:4-Quinolones; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D013806:Theophylline; C053091:lomefloxacin